PET/CT: Combining Function and Morphology

  • T. F. Hany
  • G. K. von Schulthess
Conference paper
Part of the Ernst Schering Research Foundation Workshop book series (SCHERING FOUND, volume 49)


Positron Emission Tomography Positron Emission Tomography Imaging Radiation Treatment Planning Positron Emission Tomogra Ammonia Positron Emission Tomography 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. ACS ACS: Cancer Facts & Figures 2001. American Cancer Society, National Home Office, Atlanta, pp 1–44Google Scholar
  2. Adams S, Baum RP, Stuckensen T, et al. (1998) Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 25:1255–1260PubMedCrossRefGoogle Scholar
  3. Bailet JW, Abemayor E, Jabour BA, et al. (1992) Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 102:281–288PubMedGoogle Scholar
  4. Bangerter M, Moog F, Buchmann I, et al. (1998) Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease. Ann Oncol 9:1117–1122PubMedCrossRefGoogle Scholar
  5. Burger C, Goerres G, Schoenes S, et al. (2002 a) PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients. Eur J Nucl Med Mol Imaging 29:922–927PubMedCrossRefGoogle Scholar
  6. Burger I, Goerres GW, Von Schulthess GK, et al. (2002b) PET/CT: Diagnostic improvement in recurrent colorectal carcinoma compared to PET alone. Radiology 225:424Google Scholar
  7. Ciernik IF, Dizendorf E, Baumert BG, et al. (2003) Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): A feasibility study. International Journal of Radiation Oncology Biology Physics 57:853–863Google Scholar
  8. DeGrado TR, Coleman RE, Wang S, et al. (2001) Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 61:110–117PubMedGoogle Scholar
  9. Delbeke D, Vitola JV, Sandier MP, et al. (1997) Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 38:1196–1201PubMedGoogle Scholar
  10. Dizendorf EV, Baumert BG, von Schulthess GK, et al. (2003) Impact of whole-body F-18-FDG PET on staging and managing patients for radiation therapy. J Nucl Med 44:24–29PubMedGoogle Scholar
  11. Falk PM, Gupta NC, Thorson AG, et al. (1994) Positron emission tomography for preoperative staging of colorectal carcinoma. Dis Colon Rectum 37:153–156PubMedCrossRefGoogle Scholar
  12. Flamen P, Stroobants S, Van Cutsem E, et al. (1999) Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol 17:894–901PubMedGoogle Scholar
  13. Goerres GW, Schmid DT, von Schulthess GK, et al. (2003) FDG PET/CT improves the confidence of anatomic assignment of cancer lesions in the head and neck: a comparison with FDG PET and contrast-enhanced CT. J Nucl Med 44:417–zzzGoogle Scholar
  14. Goldberg RM, Fleming TR, Tangen CM, et al. (1998) Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med 129:27–35PubMedGoogle Scholar
  15. Gupta NC, Maloof J, Gunel E (1996) Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 37:943–948PubMedGoogle Scholar
  16. Hany TF, Steinert HC, Goerres GW, et al. (2002) PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 225:575–581PubMedCrossRefGoogle Scholar
  17. Higashi K, Ueda Y, Seki H, et al. (1998) Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 39:1016–1020PubMedGoogle Scholar
  18. Huang SC, Phelps ME, Hoffman EJ, et al. (1980) Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 238:E69–E82PubMedGoogle Scholar
  19. Jaszczak RJ, Hoffman ED (1995) Positron Emission Tomography (PET): scatter and attenuation, in Wagner HN, Szabo Z, Buchanan JW (eds): Principles of nuclear medicine, 2nd edn. WB Saunders, PhiladelphiaGoogle Scholar
  20. Jerusalem G, Beguin Y, Fassotte MF, et al. (2000) Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin’s lymphoma. Haematologica 85:613–618PubMedGoogle Scholar
  21. Jerusalem G, Beguin Y, Fassotte MF, et al. (1999) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429–433PubMedGoogle Scholar
  22. Jerusalem G, Hustinx R, Beguin Y, et al. (2002) The value of positron emission tomography (PET) imaging in disease staging and therapy assessment. Ann Oncol 13:227–234PubMedGoogle Scholar
  23. Kau RJ, Alexiou C, Laubenbacher C, et al. (1999) Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting. Arch Otolaryngol Head Neck Surg 125:1322–1328PubMedGoogle Scholar
  24. Kinahan PE, Townsend DW, Beyer T, et al. (1998) Attenuation correction for a combined 3D PET/CT scanner. Med Phys 25:2046–2053PubMedCrossRefGoogle Scholar
  25. Lardinois D, Weder W, Hany TF, et al. (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500–2507PubMedCrossRefGoogle Scholar
  26. Moog F, Bangerter M, Kotzerke J, et al. (1998a) 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 16:603–609PubMedGoogle Scholar
  27. Moog F, Bangerter M, Diederichs CG, et al. (1998b) Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 206:475–481PubMedGoogle Scholar
  28. Moog F, Bangerter M, Diederichs CG, et al. (1997) Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 203:795–800PubMedGoogle Scholar
  29. Namdar M, Hany TF, Burger C, et al. (2003) Combined computed tomography-angiogram and positron emission tomography perfusion Imaging for assessment of coronary artery disease in a novel PET/CT: a pilot feasibility study. J Am Coll Cardiol 41:439ACrossRefGoogle Scholar
  30. Patz EF, Jr, Lowe VJ, Hoffman JM, et al. (1993) Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 188:487–490PubMedGoogle Scholar
  31. Patz EF, Jr, Lowe VJ, Hoffman JM, et al. (1994) Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology 191:379–382PubMedGoogle Scholar
  32. Phelps ME (1981) Positron computed tomography studies of cerebral glucose metabolism in man: theory and application in nuclear medicine. Semin Nucl Med 11:32–49PubMedCrossRefGoogle Scholar
  33. Ruers TJ, Langenhoff BS, Neeleman N, et al. (2002) Value of positron emission tomography with [F-18] fluorodeoxyglucose in patients with colorec-tal liver metastases: a prospective study. J Clin Oncol 20:388–395PubMedCrossRefGoogle Scholar
  34. Schaefer NG, Hany TF, Taverna C, et al. (2003) FDG PET/CT versus contrast enhanced CT in aggressive non-Hodgkin lymphoma and Hodgkin’s disease. J Nucl Med 44:272Google Scholar
  35. Stokkel MP, Moons KG, ten Broek FW, et al. (1999) 18F-fluorodeoxyglucose dual-head positron emission tomography as a procedure for detecting simultaneous primary tumors in cases of head and neck cancer. Cancer 86:2370–2377PubMedCrossRefGoogle Scholar
  36. Stumpe KD, Urbinelli M, Steinert HC, et al. (1998) Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 25:721–728PubMedCrossRefGoogle Scholar
  37. Webb WR, Gatsonis C, Zerhouni EA, et al. (1991) CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 178:705–713PubMedGoogle Scholar
  38. Webb WR, Sarin M, Zerhouni EA, et al. (1993) Interobserver variability in CT and MR staging of lung cancer. J Comput Assist Tomogr 17:841–846PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • T. F. Hany
    • 1
  • G. K. von Schulthess
    • 2
  1. 1.Dept. of Medical Radiology/Division of Nuclear MedicineUniversity Hospital ZurichZurichSwitzerland
  2. 2.Clinic and Policlinic of Nuclear MedicineUniversity Hospital ZÜrichZurichSwitzerland

Personalised recommendations